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ABSTRACT: Down syndrome (DS) is one of the most common genetic causes of intellectual disability and is
characterized by a number of behavioral as well as cognitive symptoms. Many of the neuropathological features
of early-onset Alzheimer’s disease (AD) including senile plaques and neurofibrillary tangles (NFTs) are also
present in people with DS as a result of triplication of the amyloid precursor gene on chromosome 21. Evidence
suggests that harboring one or both apolipoprotein E4 (APOE4) alleles may increase the risk for AD due to the
proteolytic cleavage of apoE4 and a subsequent loss of function. To investigate a role for the apoE proteolysis
in vivo, we compared three autopsy groups; 7 DS with AD neuropathology cases over 40 years, 5 young DS
cases without AD pathology under 40 years (YDS) and 5 age-matched control cases over 40 years by
immunohistochemistry utilizing an antibody that detects the amino-terminal fragment of apoE. Application of
this antibody, termed the amino-terminal apoE fragment antibody (nApoECF) revealed labeling of pyramidal
neurons in the frontal cortex of YDS cases, whereas in the DS-AD group, labeling with nApoECF was
prominent within NFTs. NFT labeling with nApoECF was significantly greater in the hippocampus versus the
frontal cortex in the same DS-AD cases, suggesting a regional distribution of truncated apoE. Colocalization
immunofluorescence experiments indicated that 52.5% and 53.2% of AT8- and PHF-1-positive NFTs,
respectively, also contained nApoECF. Collectively, these data support a role for the proteolytic cleavage of
apoE in DS and suggest that apoE fragmentation is closely associated with NFTs.

Key words: Alzheimer’s disease, beta-amyloid, paired helical filaments, proteolysis, neurofibrillary tangles,
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Down syndrome (DS) is a chromosomal disorder
(Trisomy 21) that is caused by nondisjunction resulting in
the triplication of the chromosome 21 in the large majority
of cases and is the most commonly identified genetic
cause of intellectual disability in the United States [1, 2].
In addition to several phenotypic features of DS [3-7],
people with DS also exhibit mild to moderate cognitive
dysfunction [8] delayed verbal short-term memory and
neurobehavioral problems [9]. In addition to the
phenotypic and cognitive impairments associated with

this disorder, an increased risk of Alzheimer’s disease
(AD) in patients with DS is also well established. In DS,
the postmortem findings of senile plaques and
neurofibrillary plaques (NFTs) is assumed to be caused by
the overexpression of the amyloid precursor protein
(APP) following triplication of chromosome 21 and
accumulation of beta-amyloid. In DS, nearly all adults
over 35 to 40 years of age exhibit key neuropathological
changes characteristic of AD including the formation of
extracellular plaques of beta-amyloid and NFTs [10-12].
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Previous studies have shown a substantial increase in
the cumulative incidence of dementia in adults with DS
between ages 50 and 72 [13]. Risk factors that affect the
age of onset of dementia in DS include harboring the
APOE4 allele as well as high levels of plasma betaamyloid 1-42 [14]. In contrast, there is a reduced risk for
the onset of dementia associated with APOE2 allele and
atypical karyotypes in DS [14]. The human APOE gene is
polymorphic resulting in three major isoforms, apoE2,
apoE3, and apoE4, which differ by single amino acid
substitutions involving cysteine-arginine replacements at
positions 112 and 158 [15]. Inheritance of one copy of
the APOE4 allele increases the disease risk of AD fourfold, while two copies enhances disease risk
approximately ten-fold [16]. Thus, harboring the APOE4
allele represents the most significant late-onset genetic
risk factor. A recent study highlighted this risk by
demonstrating that the lifetime risk of AD at the age of 85
without reference to the APOE genotype was 11% in
males and 14% in females [17]. At the same age, this risk
ranged from 51% for APOE 4/4 male carriers to 60% for
APOE 4/4 female carries, consistent with a semidominant inheritance pattern [17]. The preponderance of
evidence suggests that harboring the APOE4 allele in DS

also increases AD disease risk, although to a lower extent
to what has been found in AD [18]. Additionally, studies
suggest harboring the APOE4 allele leads to earlier
mortality in the DS population that is independent of the
risk of dementia [19, 20]. How apoE4 increases the risk
for AD is unknown, however, evidence suggests that the
enhanced susceptibility of apoE4 to proteolysis as
compared to E2 and E3 may play a critical role leading to
loss of function including impaired cholesterol transport
and beta-amyloid clearance [21]. The purpose of the
current study was to investigate whether apoE proteolysis
is prevalent in postmortem DS human brain sections
utilizing an antibody that detects the amino-terminal
fragment of apoE (herein termed, nApoECF antibody)
[22]. Previous studies carried out with the nApoECF
antibody demonstrated that it consistently labeled NFT’s
in sporadic AD, Picks disease and vascular dementia in
addition to the labeling of blood vessels and reactive
astrocytes [22-24]. Our findings using the nApoECF
antibody in the present study support a role for the
proteolytic cleave of apoE with aging and AD in DS and
suggest that apoE fragmentation is closely associated with
mature NFTs.

Table 1. Case Demographics
Case
1
2
3

NPD
Normal
Normal
Normal

Sex
F
F
M

PMI
24
21
17

Age
46
51
57

Region
Frontal Cortex
Frontal Cortex
Frontal Cortex

4
5
6
7
8

Normal
Normal
YDS
YDS
YDS

M
M
M
M
F

5
3
24
4
36

65
67
24
31
34

9

YDS

F

12

39

10

YDS

M

5

33

11

DS-AD

M

6

46

12

DS-AD

M

18

56

13

DS-AD

F

5

57

14
15
16
17

DS-AD
DS-AD
DS-AD
DS-AD

M
M
F
M

10
2
3
2.2

66
67
57
49

Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
Frontal Cortex
and Hippocampus
Frontal Cortex
and Hippocampus
Frontal Cortex
and Hippocampus
Frontal cortex and
Hippocampus
Frontal cortex and
Hippocampus
Frontal cortex and
Hippocampus
Frontal Cortex
Frontal Cortex
Hippocampus
Hippocampus

Cause of Death
Multiple injuries
Cardiovascular disease
Arteriosclerotic
cardiovascular disease
Cardiac arrest
Cardiomyopathy
Cardiac arrhythmia
Pneumonia
Septic shock

APOE Genotype
N/A
N/A
N/A

Cancer

N/A

Acute bronchopneumonia

N/A

Cardiac respiratory failure

2/3

Alzheimer’s disease

3/3

Other

3/3

Congestive heart failure
Pneumonia
Alzheimer’s disease
Pneumonia

N/A
N/A
3/3
3/3

N/A
N/A
N/A
N/A
N/A

PMI, postmortem interval in hours; NPD, neuropathological diagnosis; YDS, young Down Syndrome; DS-AD, Down syndrome with Alzheimer’s
disease pathology. For all DS-AD cases, the Braak & Braak staging was VI/C.
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MATERIALS AND METHODS
Subjects
Autopsy brain tissue was obtained from three groups –
Young DS (YDS), DS with sufficient neuropathology for
AD (DS-AD) and age matched controls for the DS-AD
cases. Case demographics are presented in Table 1. Fixed
hippocampal tissue sections used in this study were
provided by either the Institute for Memory Impairments
and Neurological Disorders at the University of
California, Irvine or the NIH NeuroBioBank. Approval
from Boise State University Institutional Review Board
was not obtained due to the exemption granted that all
tissue sections were fixed and received from University of
California, Irvine. Brain tissue obtained from University
of California, Irvine were anonymized and never
identified except by case number. Tissue donors or their
next of kin provided informed signed consents to the
Institute for Memory Impairments and Neurological
Disorders for the use of their tissues in research (IRB
2014-1526). AD was established in DS cases based upon
published consensus neuropathological criteria [25].
Immunohistochemistry
Free-floating 40 μm-thick sections were used for brightfield immunohistochemical studies as previously
described [23]. The primary antibody was visualized
using brown DAB substrate (Vector Laboratories).
Immunofluorescence Microscopy
Primary antibodies utilized included PHF-1 (mouse
monoclonal, 1:1,000), AT8 (mouse monoclonal, 1:250)
and nApoECF (rabbit monoclonal, 1:100). PHF-1 was a
generous gift from Dr. Peter Davies (Albert Einstein
College of Medicine, Bronx, NY). The AT8 antibody was
purchased from Pierce, ThermoFisher Scientific Inc.
(Waltham, MA). The anti-apoE4 full-length C-terminal
mouse antibody was purchased from Abgent (San Diego,
CA). The anti-apoE4 full-length N-terminal mouse
antibody was purchased from Aviva Systems Biology
Corp. (San Diego, CA). No antigen retrieval methods
were employed. For double-label immunofluorescence
co-localization studies, experiments were conducted as
previously described [23]. Briefly, an Olympus BX60
microscope with fluorescence capability equipped with a
MagnaFire SP software system for photomicrography was
employed
for
microscopic
observation
and
photomicrography of the DAB-labeled and fluorescent
sections. The fluorescent molecules were excited with a
100-W mercury lamp. Fluorescent-labeled molecules

Aging and Disease • Volume 7, Number 3, June 2016

Proteolytic Cleavage of apoE in the Down Syndrome Brain

were detected using a filter set having a 460-500-nm
wavelength band pass excitation filter, a 505-nm dichroic
beam splitter, and a 510-560-nm band pass emission filter.
Confocal microscopy
Confocal immunofluorescence imaging was as previously
described [23], and primary antibodies were visualized
with secondary antibodies tagged with either Alexa Fluor
488 or Alexa Fluor 555 (Invitrogen, Carlsbad, CA).
Images were taken with a Zeiss LSM 510 Meta system
combined with the Zeiss Axiovert Observer Z1 inverted
microscope and ZEN 2009 imaging software (Carl Zeiss,
Inc., Thornwood, NY). Confocal Z-stack and single plane
images were acquired with an Argon (488 nm) and a
HeNe (543 nm) laser source. Z-stacks images were
acquired using a 20x Plan-Apochromat (NA 0.8)
objective, emission band passes of 505-550 nm for the
detection of the nApoECF (green channel, Alexa Fluor
488) and 550-600 nm for detection of PHF-1 (red channel,
Alexa Fluor 555). All images displayed are 2-D, maximal
intensity projections generated acquired Z-stacks. The
optical depth used varied between experiments but was in
the range of 10-25 µm in the Z-plane. Single plane images
were acquired with a 63x Plan-Apochromat oilimmersion objective (NA 1.4) with emission long pass of
505 nm for the detection of the nApoECF antibody (green
channel, Alexa Fluor 488) and 550-600 nm for the
detection of PHF-1 (red channel, Alexa Fluor 555).
Statistical analysis
To determine significant differences between the various
cohorts, an ANOVA was used to test for group differences
in cell counts. IBM SPSS Statistics (Ver. 22) was used
for statistical analyses with an alpha level of 0.05.
To determine the percent co-localization, a
quantitative analysis was performed as described
previously [23] by taking 20X immunofluorescence,
overlapping images from three different fields in area
CA1 in three separate DS-AD cases. Capturing was by
using a 2.5x photo eyepiece, and a Sony high resolution
CCD video camera (XC-77). For example, to determine
the percent co-localization between nApoECF and PHF1, photographs were analyzed by counting the number of
nApoECF or PHF-1-positive NFTs alone per 20X field
for each case, and the number of cells labeled with both
PHF-1 and nApoECF. Data are representative of the
average number (±S.D.) of each antibody alone or colocalized with both antibodies in each 20X field (3 fields
total for 4 different cases). Statistical differences in this
study were determined using Student’s two-tailed T-test
employing Microsoft Office Excel. We used the
Kolmogorov-Smirnov test of normality (SPSS Statistics)
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and all groups were normally distributed and thus, it was
appropriate to use an ANOVA for the analysis. To
determine any possible correlations between the various
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groups, Pearson’s coefficients were determined using
Microsoft Office Excel.

Figure 1. Localization of an amino-terminal fragment of apoE in the frontal cortex of Down’s syndrome.
(A-B): Application of the nApoECF antibody in frontal cortex tissue sections from YDS cases revealed labeling
predominantly within pyramidal neurons (arrows, low magnification Panel A) and (arrows, high magnification
Panel B). (C): In contrast, in DS-AD cases, in addition to neuronal staining, more mature, fibrillary NFTS were
labeled with the nApoECF antibody (arrows), whereas little immunoreactivity was observed in age-matched
control cases (D). (E): A least significant difference post hoc test analysis of the number of nApoECF-positive
neurons and NFTs in frontal cortex indicated a significant difference between DS-AD cases and age-matched
controls (p= 0.02) and YDS groups (p = 0.05). For all three groups, n = 5, ±S.E.M. All scale bars represent 10 µm
except for Panel D, which represents 50 µm.
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Figure 2. Localization of an amino-terminal fragment of apoE in the hippocampus of Down’s syndrome.
Application of the nApoECF antibody in hippocampal tissue sections revealed very little labeling in YDS cases (A) or
in age-matched controls (C), however, strong immunolabeling of NFTs was observed in DS-AD cases (B). (D): Three
DS-AD cases were quantified (±S.D.) for the number of nApoECF-positive NFTs comparing hippocampal versus frontal
cortex regions. The data revealed a clear difference between the numbers of labeled NFTs between the two regions with
the hippocampus giving consistently higher numbers. Case #1, #2, and #3 correspond to subjects 13, 12, and 11,
respectively, as listed in Table 1. All scale bars for Panels A and C represent 50 µm and 10 µm for Panel D.
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RESULTS
Localization of the amino terminal fragment of apoE in
the frontal cortex of Down’s syndrome
To investigate a role for the apoE proteolysis in DS, an
immunohistochemical study utilizing our in house
nApoECF antibody was performed in fixed frontal cortex
and hippocampal brain sections from 7 adult DS-AD
cases, 5 YDS cases, and 5 neuropathogically normal
cases. Case demographics for the DS-AD, YDS and
control groups are presented in Table 1. Age at death
between the control and DS-AD groups was not
statistically different (57.2 ±8.96 vs. 56.9 ±7.82). As an
initial step, we screened all cases for nApoECF
immunoreactivity using bright field microscopy.
Previous characterization of this nApoECF antibody has
indicated it to be highly specific for a neoepitope ~18 kDa
amino-terminal fragment of apoE [22]. This in house
antibody was synthesized based upon a putative proteasecleavage site at position D172 of the full-length protein
and has been extensively characterized biochemically to
show that it does not react at all with the full-length form
of apoE [22]. Application of this antibody to YDS frontal
cortex brain sections revealed specific localization
predominantly within pyramidal neurons (Figure 1A,
arrows and 1B). By contrast, application of the same
antibody revealed labeling of both mature fibrillary NFTs
(Figure 1C arrows) as well as neuronal staining in DSAD, while minimal immunoreactivity was observed in
normal control cases (Figure 1D). Quantitative analysis
of labeled neurons and NFTs in the frontal cortex
indicated that there was a significant main effect of group
on cell counts with controls having the fewest positive
cells, the young DS having an intermediate number of
cells and the DS-AD cases having the highest number of
positive cells (F(2, 14)=4.08 p=0.044). A significant
difference was found between the age-matched controls
and DS-AD group (p= 0.02) as well as between the YDS
and DS-AD group (p= 0.05) (Figure 1E).
Localization of the amino terminal fragment of apoE in
the hippocampus of Down’s syndrome
To determine if nApoECF labeling was specific to the
frontal cortex similar experiments were conducted on
hippocampal sections. In contrast to what was observed
in frontal cortex sections, application of the nApoECF
antibody to hippocampal sections revealed little to no
immunoreactivity in YDS and normal control cases
(Figure 2A and 2C). As observed in the frontal cortex
cases, there was strong immunolabeling of NFTs as well
as neuronal staining in DS-AD cases (Figure 2B). To
verify the observed differences between hippocampal and
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frontal cortex regions three DS-AD cases were quantified
for the number of nApoECF-positive NFTs (Figure 2D).
The results indicated that between the two regions the
hippocampus consistently had higher numbers of labeled
NFTs, suggesting a regional distribution of truncated
apoE. The three cases used in this experiment were
subjects 11 (case #3), 12 (case #2), and 13 (case #1)
(Figure 2D) (Table 1). It is noteworthy that the APOE
allele status for cases 12 and 13 was 3/3, while that for
case 11 was 2/3 (Table 1). The data indicated a
significantly higher number of identified nApoECFpositive NFTs in the hippocampus of the APOE allele 3/3
cases in comparison to the 2/3 case (Figure 2D).
Co-localization of the nApoECF antibody within NFTs
in hippocampal sections of the Down’s syndrome brain
To determine the extent of co-localization of the
nApoECF antibody, double-label immunofluorescence
studies were performed using standard NFT tangle
markers, PHF-1 and AT8 in fixed hippocampal brain
sections.
The antibody AT8 recognizes tau
phosphorylated at both serine 202 and threonine 205,
which are the first residues to be hyperphosphorylated,
whereas the antibody PHF-1 recognizes phosphorylation
at serine 396 and 404 and reacts with more mature
hyperphosphorylated forms of tau found primarily within
late-stage tangles [26-28]. Confocal immunofluorescence
microscopy revealed strong co-localization between the
nApoECF antibody and PHF-1 in the hippocampus
(Figure 3A-C). Additionally, co-localization between
nApoECF and the AT8 antibody was also evident,
however, co-localization between the two appeared to be
in distinct subcellular locations within the same tangle
bearing neurons (Figure 3D-F). Quantification of NFTs
double-labeled by PHF-1 or AT8 and nApoECF revealed
that roughly 52.5% of AT8-positive tangle bearing
neurons contained nApoECF (Pearson coefficient = 0.61), whereas 53.2% of all identified PHF-1-positive
neurons were labeled with nApoECF (Pearson coefficient
= 0.64) (Figure 3G-H).
Co-localization of nApoECF with full-length amino
terminal antibodies to apoE4 in NFTs of the Down
syndrome brain
Further double-label immunofluorescence studies were
performed utilizing an antibody specific to the aminoterminal region of full-length apoE4 and nApoECF
(Figure 4A-C) in fixed hippocampal brain sections.
Results showed strong co-localization within an apparent
NFT (arrow, Panel C) as well as blood vessels
(arrowhead, Panel C). By contrast, application of a fulllength antibody specific for the C-terminal end of apoE4
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strongly labeled blood vessels (Figure 4D, green) but
resulted in a lack of immunoreactivity and co-localization
with nApoECF within apparent NFTs (Figure 4D,

Proteolytic Cleavage of apoE in the Down Syndrome Brain

arrows). The DS-AD cases used for these experiments are
listed in Table 1 (11-13).

Figure 3. Co-localization of an amino-terminal fragment of apoE within NFTs in hippocampal tissue sections of the Down’s
syndrome brain. (A-C): Representative confocal immunofluorescence double-labeling utilizing the nApoECF antibody (green, Panel
A) and PHF-1 (red, Panel B) revealed strong co-localization of the two antibodies within a NFT located in the hippocampus (Panel C).
(D-F): Identical to Panels A-C with the exception of AT8 (red) being employed. For Panels A-F, images were captured from the CA1
region of the hippocampus in representative DS-AD cases. (G and H): Quantification of NFTs double-labeled by PHF-1, AT8, and
nApoECF. For both panels, data show the number of NFTs labeled with nApoECF alone (blue bar), AT8 (G) or PHF-1 (H) alone (green
bars) or those NFTs that were labeled with both antibodies (red bars). NFTs were identified in a 20X field within hippocampal tissue
sections by immunofluorescence overlap microscopy (n=3 fields using three different DS cases) ±S.E.M. For Panel G there were no
statistical differences between the various test groups. Data indicated that roughly 52.5% of AT8-positive NFTs also contained
nApoECF, whereas 53.2% of all identified PHF-1-positive NFTs were labeled with nApoECF.
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Figure 4. Co-localization of nApoECF with a full-length amino-terminal antibody to apoE4 in NFTs of the Down Syndrome
brain. (A-C): Representative confocal immunofluorescence double-labeling in CA1 region of the hippocampus in DS-AD cases
utilizing an antibody that recognizes the amino-terminal region of full-length apoE4 (green, A) and nApoECF (red, B), with the overlap
image shown in Panel C. Strong co-localization was indicated in both apparent NFTs and blood vessels (yellow, C). (D): In contrast, no
co-localization with nApoECF was observed in a similar experiment using a full-length antibody to the C-terminal end of apoE4, which
strongly labeled blood vessels (green, D), but not NFTs (arrows, D).
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DISCUSSION
Harboring the APOE4 allele enhances the risk for AD and
several reports have suggested that the proteolytic
cleavage of apoE4 into N- and C-terminal fragments may
provide a mechanism by which this protein contributes to
AD pathogenesis (for recent review, see [21]). ApoE4 is
highly susceptible to proteolysis compared to apoE3, and
apoE4 fragments (14–20 kDa) have been identified in the
AD brain [22, 29, 30]. However, whether apolipoprotein
E4 contributes to an earlier onset of dementia or increased
mortality in DS patients is still a matter of debate. Due to
the location of the amyloid precursor protein on
chromosome 21, many of the neuropathological features
of early-onset AD including senile plaques and
neurofibrillary tangles are also present in people with DS
who are either demented or nondemented. Significant
advances in medical treatment have increased longevity
in people with DS resulting in an increased population that
may be vulnerable to many of the same risk factors as
those with sporadic AD. Few genetic risk factors
associated with late onset AD carry a larger risk potential
for AD than that of the APOE4 allele. Inheritance of one
copy of the allele increases risk four-fold while
inheritance of two copies increases risk ten-fold [16]. The
preponderance of evidence suggests that harboring the
APOE4 allele also increases dementia risk in DS, albeit to
a lower extent than what is observed in AD [18].
Therefore, we sought to investigate whether apoE
proteolysis is prevalent in postmortem DS human brain
sections utilizing an in house antibody that detects the
amino-terminal fragment of apoE. In AD this antibody,
termed the amino-terminal apoE cleavage-fragment
(nApoECF) antibody, predominantly labeled NFTs and
co-localized with other tangle markers including AT8 and
PHF-1 [22]. It is noteworthy that in AD, the nApoECF
antibody is known to recognize fragmented E3 and E4
[22]. In the present study utilizing the nApoECF antibody,
we examined fixed frontal cortex and hippocampal brain
sections from seven adult DS-AD cases. An important
caveat of the present study was the limited clinical
information available regarding the APOE allele status of
the patients used in this study. Therefore, we were unable
to evaluate our findings in terms of APOE4 status.
Application of this antibody to frontal cortex tissues
revealed labeling of mature NFTs as well as neuronal
staining in DS-AD, while staining was restricted to
pyramidal neurons in YDS cases. Not surprisingly, we
did not observe labeling of NFTs in our YDS group as this
is an age when NFTs are typically not present.
Interestingly, in addition to NFTs, the nApoECF
antibody also labeled neurons in both frontal and
hippocampal regions. In this regard, there was a
significant difference in the number of labeled neurons in
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controls versus the DS-AD group and the YDS versus the
DS-AD group. In general, labeled neurons
morphologically appeared normal as compared to NFTs.
In contrast, minimal immunoreactivity was observed in
age-matched control cases. Results of experiments on
hippocampal
sections revealed
little
to
no
immunoreactivity in YDS and age matched control cases,
and strong immunolabeling of NFTs as well as neuronal
staining in DS-AD similar to what was seen in frontal
cortex.
Another finding in the present study was the
significant difference in the number of labeled nApoECFNFTs in the hippocampus versus frontal cortex in the DSAD group. There was significantly higher number of
labeled NFTs in the hippocampus as compared to frontal
cortex. This suggests the appearance of the fragmentation
of ApoE coincides with the normal progression of NFT
pathology from the hippocampus to the frontal cortex that
is a well-characterized finding in AD [31]. Alternatively,
the data could imply that in these three cases, there were
substantially more NFTs present in the hippocampus as
compared to the frontal cortex as this analysis was not
performed. For these experiments, the APOE genotype of
two of the three cases was 3/3, while that of the third was
2/3. The data indicated a significantly higher number of
identified nApoECF-positive NFTs in the hippocampus of
the 3/3 cases in comparison to the DS-AD 2/3 case (Figure
2D). These results would seem to support previous
studies demonstrating that apoE2 is the most stable
isoform [32] and may provide a rationale as to the
protective role of harboring the APOE2 allele in
preventing dementia [33].
To further characterize the labeling of nApoECF
within NFTs, double-label immunofluorescence confocal
studies were performed using PHF-1 and AT8 antibodies.
Results showed strong co-localization between the
nApoECF antibody and PHF-1 as well as AT8 in
hippocampal sections. With respect to AT8, our results
suggested that even though the two antibodies colocalized within the same tangle bearing neurons, they
appeared to be spatially separated. This was in contrast to
PHF-1, where strong overlap with nApoECF was
observed. In addition, statistical analysis revealed a
negative correlation between AT8 and nApoECF (-0.61),
while a positive correlation was found between PHF-1
(0.64). These data are suggestive that nApoECF
accumulation occurs in more mature forms of NFTs and
that the fragmentation of apoE is most likely a late event
in the evolution of tangle pathology.
Double-label confocal immunofluorescence studies
using an antibody specific to the amino-terminal region of
full-length apoE4 and nApoECF showed strong colocalization in NFTs as well as blood vessels. By contrast,
application of a full-length antibody specific to the C-
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terminal end of apoE4 resulted in a lack of
immunoreactivity in NFTs but strongly labeled blood
vessels. These results confirm our previous findings in
AD, and support the specificity of the nApoECF antibody
to the amino-terminal fragment of apoE4 [21]. In
comparison of our previous study that examined lateonset AD cases we found a similar relationship between
the presence of apoE fragmentation and its’ localization
in NFTs of DS-AD cases. These data would suggest that
the pathological events associated with apoE
fragmentation in early onset-AD are similar when
compared to late onset AD.
In summary, we have documented the presence of an
amino-terminal apoE fragment in both the frontal cortex
and hippocampus of the DS-AD brain. The presence of
this fragment within NFTs of DS-AD brain tissue
suggests these two events may be causally linked.
Previous studies support that harboring the APOE4 allele
increases the risk for dementia in DS patients albeit to a
lower extent to what has been found in AD. The present
findings suggest that apoE fragmentation is present within
the DS brain and could provide a rationale as to the
enhanced dementia risk associated with the APOE4 allele
in DS. However, to best address this hypothesis, it would
be necessary to compare autopsy cases with and without
dementia, in addition to the presence or absence of AD
neuropathology. Our data support a role for apoE
proteolysis in DS-AD generating an amino-terminal
fragment that accumulated with NFTs. Our study may
provide impetus for further research on the potential
impact of the APOE4 risk factor on dementia in older DS
populations.
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